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Muscle IGF-I levels in
hemodialysis patients
To the Editor: We read with great interest Wang et al’s
paper [1] describing reduced skeletal muscle mRNA
levels for insulin-like growth factor (IGF)-IEa, IGF-II,
and the IGF type 1 receptor in hemodialysis (HD) pa-
tients. While the low levels of IGF-IEa mRNA relative
to healthy controls is anticipated, the elevated muscle
IGF-I protein level (mIGF-I) reported is at odds with
the diminished levels, relative to healthy controls previ-
ously reported in our HD patients [2] and animal mod-
els of chronic renal failure (CRF) (e.g. [3]). An obvious
difference between these studies is that in contrast to
our patients and CRF rats, the HD patients recruited by
Wang et al were not muscle wasted. This supports our
contention that mIGF-I may play an important role in
muscle atrophy in CRF populations.
Notwithstanding species and methodologic differ-
ences, we were also surprised by the huge disparity in
mean mIGF-I levels reported by this group for HD pa-
tients and CRF rats [1, 3]. Assuming a protein content of
15.5% in wet skeletal muscle for nonobese humans [4],
the 131 and 100 ng IGF-I/mg wet muscle values reported
by Wang et al convert to 845 and 645 ng IGF-I/mg muscle
protein for HD patients and controls, respectively. These
values are 1 to 2×105 greater than those reported by Ding
et al (0.0042 and 0.0069 ng/mg muscle protein for CRF
and control rats, respectively). Are the units correctly
stated in these papers? Additionally, the serum IGF val-
ues in Wang et al’s paper need to be reported as ng/mL,
not lg/mL, to be correct.
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Anti-proteinase 3 antibody
binding to neutrophils as
demonstrated by confocal
microscopy
To the Editor: We read with great interest the article
by Van Rossum et al [1] and wish to provide supplemen-
tary microscopic evidence of binding of anti-neutrophil
cytoplasm antibodies (ANCA) to a subset of neutrophils.
Following the report by Abdel-Salam et al [2] of a fail-
ure of ANCA to bind to neutrophils, we investigated
binding of anti-PR3 antibody positive serum from pa-
tients with systemic vasculitis to human neutrophils using
indirect immunofluorescence and confocal microscopy,
as detailed in Figure 1. The priming and staining proce-
dure was virtually identical to that used by Van Rossum
et al, with the addition of an incubation step with
the neutrophil marker CD16. Our results support their
findings, with membrane staining of a fraction of neu-
trophils incubated with anti-PR3–positive serum. Thus,
the hypothesis that ANCA binding in vivo results in
dysregulated degranulation of neutrophils [3] remains
viable.
